- Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
- Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
- Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
- Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
- Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
- Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2]
- Continuing operations net sales up 7% (cc[1], +2% USD) driven by Innovative Medicines:
- Cosentyx was USD 791 million, +41% (cc) with strong demand growth in all indications and regions
- Entresto grew to USD 357 million, +85% (cc) including the benefit from new data on hospital initiation
- Oncology sales grew 9% (cc) mainly driven by Lutathera (USD 106 million), Promacta (USD …
- Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
- Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
- Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need
HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …
- Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
- Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
- Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need
HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …
- Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim
- Pegfilgrastim is used to reduce the incidence of neutropenia, one of the most serious side effects of chemotherapy, hospitalizing 60,000 US cancer patients each year1
- Sandoz is committed to fostering biosimilar competition, to offer high-quality, cost-effective medicines and contribute to a more sustainable healthcare system
Holzkirchen, April 3, 2019 – …
- Richard Francis, CEO Sandoz, to step down on March 31, 2019
- Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz
Basel, March 14, 2019 – Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.
Vas Narasimhan said; “I would …
- Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists
- Winning ideas proposed innovative uses of artificial intelligence, mobile apps and digital therapeutics to address healthcare access challenges
- Sandoz invited people worldwide to “reimagine access to healthcare” by identifying practical, scalable digital solutions to address unmet medical needs
Austin, Texas, March 10, 2019 – Sandoz, a Novartis division, today announced the winners of the 2019 Sandoz …
- Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
- The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
- This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy
Holzkirchen, January 31, 2019 – Sandoz, a Novartis division, is honored to announce that it has been officially certified “Global Top Employer 2019” …
- Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers:
- Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc)
- Oncology BU grew 9% (cc) driven by AAA[2] (USD 0.4 billion) including Lutathera, Promacta/Revolade USD 1.2 billion (+35% cc) and Tafinlar + Mekinist USD 1.2 billion (+31% cc)
- Full year core[1] operating income grew 8% mainly driven by higher sales and gross margin expansion
- Net income was USD …
Princeton, New Jersey, January 16, 2019 – Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors.
SYMJEPI will be rolled out through a phased launch, first in the institutional setting – an established channel where Sandoz Inc. has significant experience and knowledge – followed by introduction into …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia